The development of the Ebola vaccine involved extensive [clinical trials](). The rVSV-ZEBOV vaccine, also known as Ervebo, is one of the most well-known vaccines. It was developed by Merck and received prequalification from the World Health Organization (WHO) in 2019. The vaccine's efficacy was demonstrated during the [2014-2016 West Africa Ebola outbreak](), where it showed high effectiveness in preventing EVD.
